SEARCH

SEARCH BY CITATION

References

  • 1
    Editors of the Drafting Committee for Hepatitis Management Guidelines: the Japan Society of H. Guidelines for the Management of Hepatitis C Virus Infection: First edition, May 2012, The Japan Society of Hepatology. Hepatol Res 2013; 43: 134.
  • 2
    Driggers EM, Hale SP, Lee J, Terrett NK. The exploration of macrocycles for drug discovery – an underexploited structural class. Nat Rev Drug Discov 2008; 7: 608624.
  • 3
    Tsantrizos YS. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061 – from the NMR tube to the clinic. Biopolymers 2004; 76: 309323.
  • 4
    Lenz O, Verbinnen T, Lin TI et al. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 2010; 54: 18781887.
  • 5
    Lin TI, Lenz O, Fanning G et al. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother 2009; 53: 13771385.
  • 6
    Hayashi N, Seto C, Kato M, Komada Y, Goto S. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol 2013; doi: 10.1007/s00535-013-0875-1 [Epub ahead of print].
  • 7
    Fried MW, Buti M, Dore GJ et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-Naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013; 58: 19181929.
  • 8
    Zeuzem S, Berg T, Gane E et al. TMC435 in HCV genotype 1 patients who have failed previous pegylated interferon/ribavirin treatment: final SVR24 results of the ASPIRE trial. J Hepatol 2012; 56: S12.
  • 9
    Hayashi N, Goto S. A study of the efficacy of combination therapy including simeprevir (TMC435) in the treatment of genotype 1 hepatitis C (CONCERTO-1 trial). Kanzo 2013; 54: A24.
  • 10
    Izumi N, Hayashi N, Goto S. A study of the efficacy of retreatment with simeprevir (TMC435) in the treatment of genotype 1 hepatitis C (CONCERTO-2/3 trial). Kanzo 2013; 54: A156.
  • 11
    Suzuki F, Hayashi N, Goto S, Kumada H. A study of the efficacy of combination therapy with simeprevir (TMC435), peginterferon α-2b and ribavirin in the treatment of genotype 1 hepatitis C (CONCERTO-4 trial). Kanzo 2013; 54: A157.
  • 12
    Jacobson I, Dore G, Foster G et al. Simeprevir (tmc435) with peginterferon/ribavirin for chronic HCV Genotype-1 infection in treatment-naïve patients: results from QUEST-1, a phase III trial. J Hepatol 2013; 58: S568.
  • 13
    Manns M, Marcellin P, Fred Poordad F et al. Simeprevir (TMC35) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-2, a phase III trial. J Hepatol 2013; 58: S568.
  • 14
    Lawitz E, Forns X, Zeuzem S et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: results from PROMISE, a phase III trial. Gastroenterology 2013; 144: S151.
  • 15
    Huisman M, Snoeys J, Monbaliu J et al. In vitro studies investigating the mechanism of interaction between tmc435 and hepatic transporters. Hepatology 2010; 52: 461A.
  • 16
    Pharma J. Antiviral agent “Sovriad capsule 100mg” package insert. 2013.
  • 17
    Lenz O, Fevery B, Vijgen L et al. TMC435 in patients infected with HCV genotype 1 who have failed previous pegylated interferon/ribavirin treatment: virologic analyses of the ASPIRE Trial. J Hepatol 2012; 56: S5.
  • 18
    Hara T, Akuta N, Suzuki F et al. A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C. J Med Virol 2013; 85: 17461753.